ACE-031

ACE-031 is a synthetic decoy receptor — specifically, a soluble form of the activin receptor type IIB (ActRIIB) fused to a human antibody fragment. It was originally developed by Acceleron Pharma as an investigational therapy for muscular dystrophy. Instead of being a small peptide, it is a larger biologic engineered to circulate in the bloodstream and intercept signaling molecules before they can reach their natural receptors on muscle cells. It is not approved by the FDA for any human indication and is sold strictly for laboratory research.

Your body produces a built-in brake on muscle growth called myostatin, along with related molecules like activin A. These signals tell your muscles, 'that's enough — stop growing.' ACE-031 is studied as a way to soak up those braking signals before they reach your muscles. Think of it like a sponge floating around the bloodstream, mopping up the 'stop growing' messages so the natural 'keep growing' signals dominate. In animal and early human research, this resulted in measurable increases in lean muscle mass.

ACE-031 mimics the outer portion of the ActRIIB receptor that normally sits on muscle cell membranes. Myostatin, activin A, and GDF-11 all bind to ActRIIB to suppress muscle growth. By introducing a free-floating decoy version of that receptor, ACE-031 binds those ligands in circulation, preventing them from docking on real muscle-cell receptors. With the brakes released, downstream Smad2/3 signaling drops and the AKT/mTOR muscle-growth pathway is allowed to operate at higher capacity. The result in research subjects is increased lean mass and, in some studies, increased grip strength.

• •Duchenne muscular dystrophy clinical trials
• •Sarcopenia and age-related muscle loss
• •Lean body mass increases in healthy volunteers
• •Bone mineral density changes alongside muscle gain
• •Myostatin and activin pathway biology
• •ActRIIB decoy receptor pharmacology

ACE-031 is one of the most-discussed 'myostatin inhibitor' compounds in bodybuilding and biohacking forums, alongside follistatin and YK-11. Threads usually focus on the original Acceleron clinical data — small but real increases in lean mass after just two doses — and the fact that the program was halted partly due to off-target vascular side effects (nosebleeds, telangiectasias). Reddit's r/Peptides and AnabolicMinds users routinely debate whether grey-market 'ACE-031' is even real product, given the difficulty and cost of manufacturing a fusion protein this complex.

“Soaks up the body's built-in muscle brake.”

Online discussions sometimes pair ACE-031 with follistatin-344 (a different myostatin-pathway compound) for theoretical additive effect. Others reference it alongside GH-secretagogue stacks like CJC-1295 + ipamorelin to combine independent muscle-growth pathways. These combinations exist only as informal forum protocols, not as validated research stacks.

ACE-031 is an investigational ActRIIB decoy fusion protein studied as a myostatin-pathway muscle-growth tool. Early clinical work in muscular dystrophy showed real lean-mass gains but was halted over off-target vascular effects. It remains a frequent reference point in any online discussion of myostatin inhibitors and is sold strictly for laboratory research, not human use.